• by Les Luchter , Staff Writer, December 19, 2024

The three founders of bioregulator/peptide firm Biolongevity Labs are salivating at the possibilities of  Robert F. Kennedy Jr. as incoming head of FDA’s poppa, Health & Human Resources (HHS).

“RFK actually uses my testosterone optimization therapy protocols,” brags co-founder Jay Campbell, who wrote two books on that topic and whose latest tome, “Optimize your Health with Therapeutic Peptides: Extend your Life by Becoming More Muscular, Leaner, Smarter, Injury-Free, and Younger,”” came out last year.

Campbell tells Pharma & Marketing Insider that the HHS nominee “has also been very vocal…about rolling back the horrific draconian restrictions and regulations [on] peptides and bioregulators…that are available to the public now but not supported by the FDA or Big Pharma.”

“The current regulatory environment promotes corporate interests that only support disease management” and that “don’t actually heal the root cause of disease,” complains fellow co-founder Hunter Williams. “The companies influencing policy… have a vested interest… in people being sick.”

So what could RFK-helmed regulators do for bioregulators (a form of peptides said to heal such organs as the kidneys and liver) and their like? Could the supplement statement, "Not approved or evaluated by the FDA” become a thing of the past, perhaps?

“That would be the best-case scenario,” says Williams, but “even if the FDA doesn’t put a stamp of approval on bioregulators,” he’s happy about RFK’s pre-election statement that anyone with “an active hand in blocking access to peptide stem cells, alternative healing modalities and numerous other things, ‘pack your bags’” and leave.

Saying that alternative medicines are now “constrained and basically squashed out by larger pharmaceutical interests,” Williams suggests that the new administration “just level the playing field and allow the free market to do its bidding.”

Federal regulators aren’t the only ones being influenced unduly by Big Pharma, adds Campbell. In his view, high-level digital ad sellers are also guilty.

He says that Aseir, a company he founded to sell a hair regrowth bioregulator product, was “completely blocked by Big Pharma” in its ad efforts because “in the cold traffic space of Facebook and Google and now Instagram, they would not allow any kind of peptide-based hair regrowth product to gain any kind of market for more penetration.”

Campbell says that Big Pharma’s influence and “insane amounts of money” has given it “a lot of control over cold traffic marketing. You cannot sell anything that would compete, compare or contrast with their products, which are mostly the medical-grade stuff like Rogaine and Minoxidal.” [Editor’s note: Rogaine is now sold by Kenvue, no longer part of pharma firm Johnson & Johnson, while Minoxidal is its generic version].

In any case, Biolongevity Labs is just starting its own digital advertising, says the company’s third co-founder Josh Felber. Those efforts will initially consist of Facebook ads, Google search ads, and SEO.

Then, there are influencers – starting with the three founders themselves. “We have a massive audience,” Felber boasts, “with a combined audience 500,000 to a million people.”

Biolongevity’s products themselves now come in at over 60 SKUs and play in two categories: bioregulator supplements for consumers and peptide products for researchers.

The company’s target audience, says Hunter, is men and women in the top 10% income in the U.S. between age 40 and 70, and very health-focused. “They’re usually over $100,000 a year in income. A lot of them are financially independent, but they’re also health independent.”

That also means, says Cambell, that “they don’t care about their doctor or their copay or submitting it through insurance.”

Which is good for Biolongevity, considering that prices for its products can run into hundreds of dollars.